Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
marihuana-Hartford Hospital refers to specific vaporized cannabis preparations used in clinical research conducted by the Olin Neuropsychiatry Research Center at Hartford Hospital. These preparations utilize bulk marijuana plant material provided by the National Institute on Drug Abuse (NIDA) to investigate the differential effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on human memory and brain chemistry. The research focuses on using magnetic resonance spectroscopy (MRS) to measure glutamate levels and functional MRI (fMRI) to observe neural responses during memory tasks, specifically testing the hypothesis that CBD can attenuate the cognitive impairments typically induced by THC. The material is provided in standardized doses, such as 65 mg of THC and 50 mg of CBD, to evaluate neurobiological mechanisms in healthy occasional users.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on marihuana-Hartford Hospital.